Clinical risk factors of bevacizumab-related hypertension in patients with metastatic colorectal cancer: a retrospective study
IntroductionBevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, is widely used as a first-line treatment for metastatic colorectal cancer (mCRC), with hypertension being a common adverse effect. However, there is limited data on the predisposing factors contributing to bevacizumab-in...
Gardado en:
Main Authors: | , , , , , |
---|---|
Formato: | Libro |
Publicado: |
Frontiers Media S.A.,
2024-10-01T00:00:00Z.
|
Subjects: | |
Acceso en liña: | Connect to this object online. |
Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|
Internet
Connect to this object online.3rd Floor Main Library
Número de Clasificación: |
A1234.567 |
---|---|
Copia 1 | Dispoñible |